Press Release Details

Nkarta to Participate at Upcoming Investor Conferences

Nov 02, 2022 at 8:03 AM EDT

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences:

Cowen IO Next Summit
November 11, 2022
10:40 a.m. ET – fireside chat

Stifel Healthcare Conference
November 15, 2022
8:35 a.m. ET – fireside chat

Evercore ISI HealthCONx Conference
November 29, 2022
11:20 a.m. ET – fireside chat

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website,, and a replay will be archived on the website for approximately 90 days.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.